Stocks of Adicet Bio Inc. (NASDAQ:ACET) traded higher last session on Wall Street, up 13.17% to $2.75.
According to the data, Adicet Bio Inc. (NASDAQ:ACET) has 10 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $38.00 and a low of $6.00, we find $22.50. Given the previous closing price of $2.43, this indicates a potential upside of 825.93 percent. ACET stock price is now -49.77% away from the 50-day moving average and -72.53% away from the 200-day moving average. The market capitalization of the company currently stands at $135.00M.
A total of 4 analysts have issued a hold rating and 6 have given it a buy rating. Brokers who have rated the stock have averaged $21.88 as their price target over the next twelve months.
In other news, DUBIN STEVE, Director bought 5,000 shares of the company’s stock on Jun 30. The stock was bought for $12,000 at an average price of $2.40. Upon completion of the transaction, the Director now directly owns 10,900 shares in the company, valued at $29975.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 27, Director GORDON CARL L bought 875,000 shares of the business’s stock. A total of $1,828,750 was incurred on buying the stock at an average price of $2.09. This leaves the insider owning 5,685,259 shares of the company worth $15.63 million. Insiders disposed of 486,604 shares of company stock worth roughly $1.34 million over the past 1 year. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ACET stock. A new stake in Adicet Bio Inc. shares was purchased by CARLYLE GROUP INC. during the first quarter worth $5,775,000. ERGOTELES LLC invested $361,000 in shares of ACET during the first quarter. In the first quarter, CUBIST SYSTEMATIC STRATEGIES, LLC acquired a new stake in Adicet Bio Inc. valued at approximately $135,000. D. E. SHAW & CO., INC. acquired a new stake in ACET for approximately $122,000. VERITION FUND MANAGEMENT LLC purchased a new stake in ACET valued at around $117,000 in the second quarter. In total, there are 167 active investors with 105.07% ownership of the company’s stock.
Monday’s opening bell rang with an opening price of $2.4300 for Adicet Bio Inc. (NASDAQ: ACET). During the past 12 months, Adicet Bio Inc. has had a low of $1.98 and a high of $21.87. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 13.00, and a quick ratio of 13.00. The fifty day moving average price for ACET is $5.4085 and a two-hundred day moving average price translates $9.9351 for the stock.
The latest earnings results from Adicet Bio Inc. (NASDAQ: ACET) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.72, missing analysts’ expectations of -$0.69 by -0.03. This compares to $0.10 EPS in the same period last year. For the current quarter, analysts expect ACET to generate $12.67M in revenue.
Adicet Bio Inc.(ACET) Company Profile
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin’s lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.
